CRISPR-Cas12 is used to identify genetic signatures of the coronavirus that causes COVID-19. After identifying the virus, CRISPR-Cas12 cuts in it to uncover a fluorescent molecule that shows whether COVID-19 is president.
This test can run multiple samples at once and deliver answers with 30 to 45 minutes. The researchers hope to submit their test to the FDA next week for approval.
“What we really want to develop is something like a handheld, pocket-sized device using disposable cartridges,” Charles Chiu, MD, professor of laboratory medicine at UCSF and co-lead developer of the test, told NPR.
UCSF and Mammoth Biosciences published a paper on the CRISPR-based test in Nature Biotechnology.
More articles on health IT:
New Jersey health department, University Hospital tap Epic for EHR at state field hospital
Viewpoint: We need more data to determine who has developed COVID-19 immunity
Microsoft gives hospitals free access to cyberattack notification service amid attacks: 4 details
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
